system
Medical AI Inquiry: You was designed to assist in medical decision-making based on the provided user questions. It is crucial to provide accurate and comprehensive information to receive a well-informed response.  Labels: BACKGROUND, METHODS, RESULTS. Meshes: Acute Disease, Adolescent, Adult, Aged, Aged, 80 and over, Biopsy, Drug Therapy, Combination, Female, Follow-Up Studies, Graft Rejection, Graft Survival, Humans, Immunosuppressive Agents, Inflammation, Kaplan-Meier Estimate, Kidney, Kidney Transplantation, Kidney Tubules, Male, Middle Aged, Proportional Hazards Models, Retrospective Studies, Severity of Illness Index, Treatment Outcome, Young Adult.
user
Is acute cellular rejection with isolated v-lesions associated with more favorable outcomes than vascular rejection with more tubulointerstitial inflammations? Context: The impact of isolated v-lesions on clinical outcome in biopsies with acute cellular rejection (ACR) is unclear. Two hundred and sixty-five biopsies showing the highest ACR severity for each patient were recruited and classified into four groups: (i) acute interstitial rejection (AIR) I with minimal tubulointerstitial inflammation (TI), (ii) AIR II with intensive TI, (iii) acute vascular rejection (AVR) I with minimal TI, and (iv) AVR II with intensive TI. The complete reversal rates of AIR I and AIR II groups were marginally higher than AVR I and AVR II groups (p = 0.16). At eight yr of transplantation, the death-censored graft survival (DCGS) rate of AIR I group (93.3%) was significantly higher compared with the AVR I (72.7%) or AVR II (72.9%) group. AVR I group had a similar DCGS rate with AVR II group (72.7% vs. 74.1%), whereas AVR with v1-lesion showed significantly higher graft survival (GS) rate than those with v2-lesion (70.2% vs. 45.5%). The t-lesion of AIR and v-lesion of AVR group were associated with graft loss.
assistant
The extent of TI is non-specifically associated with graft loss in biopsies with AVR; the higher grade v-lesion predicts the lower complete reversal rate and poorer long-term graft survival. Final Decision: no